Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F List

Showing results (81-90 of 212) with videos related to

Pageof 22
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2020
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic SyndromesQing Zhang, Mintallah Haider, Najla H Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 15, 2017
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid LeukemiaAbu-Sayeef Mirza, Jeffrey E Lancet, Kendra Sweet, et al.
Cancer|March 1, 2014
Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromesDavid P Steensma, Rami S Komrokji, Richard M Stone, et al.
American Journal of Hematology|December 23, 2016
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experiencePatrick T Griffin, Rami S Komrokji, Kendra Sweet, et al.
British Journal of Haematology|July 22, 2014
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemiaAnjali S Advani, Shannon McDonough, Edward Copelan, et al.
Leukemia Research|December 26, 2008
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemiaJeffrey E Lancet, Maria R Baer, George E Duran, et al.
Leukemia Research|April 17, 2009
Outcome of patients with myelodysplastic syndromes in the Veterans Administration populationRami S Komrokji, Gina M Matacia-Murphy, Najla H Al Ali, et al.
Leukemia Research|November 28, 2013
High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainmentChristopher R Cogle, Michelle R Iannacone, Daohai Yu, et al.
Scientific Reports|May 27, 2016
Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spotsJetse Scholma, Gwenny M Fuhler, Jos Joore, et al.
Health and Quality of Life Outcomes|September 10, 2009
Valuation of transfusion-free living in MDS: results of health utility interviews with patientsAgota Szende, Caroline Schaefer, Thomas F Goss, et al.
Pageof 22

Showing results (81-90 of 212) with videos related to

Sort By:
Pageof 22
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2020
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic SyndromesQing Zhang, Mintallah Haider, Najla H Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 15, 2017
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid LeukemiaAbu-Sayeef Mirza, Jeffrey E Lancet, Kendra Sweet, et al.
Cancer|March 1, 2014
Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromesDavid P Steensma, Rami S Komrokji, Richard M Stone, et al.
American Journal of Hematology|December 23, 2016
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experiencePatrick T Griffin, Rami S Komrokji, Kendra Sweet, et al.
British Journal of Haematology|July 22, 2014
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemiaAnjali S Advani, Shannon McDonough, Edward Copelan, et al.
Leukemia Research|December 26, 2008
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemiaJeffrey E Lancet, Maria R Baer, George E Duran, et al.
Leukemia Research|April 17, 2009
Outcome of patients with myelodysplastic syndromes in the Veterans Administration populationRami S Komrokji, Gina M Matacia-Murphy, Najla H Al Ali, et al.
Leukemia Research|November 28, 2013
High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainmentChristopher R Cogle, Michelle R Iannacone, Daohai Yu, et al.
Scientific Reports|May 27, 2016
Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spotsJetse Scholma, Gwenny M Fuhler, Jos Joore, et al.
Health and Quality of Life Outcomes|September 10, 2009
Valuation of transfusion-free living in MDS: results of health utility interviews with patientsAgota Szende, Caroline Schaefer, Thomas F Goss, et al.
Pageof 22